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Abstract 
Human embryonic stem cells (hESC) and induced pluripotent stem cells (iPSC) have been 
shown to successfully generate functional hematopoietic cells of multiple lineages.  One of 
the cells that these studies have shown is possible to generate are cytotoxic natural killer 
(NK) cells.  These pluripotent stem cell-derived NK cells could potentially be used as a cell-
based therapy to treat a wide range of cancers.  A potent method through which NK cells kill 
their targets is antibody-dependent cell-mediated cytotoxicity (ADCC).  During this process 
an Fc gamma receptor, CD16a, recognizes antibody coated target cells and leads to the 
stimulation of the NK cell’s cytotoxic pathways.  However, upon CD16a activation, a 
metalloprotease known as ADAM17 has been shown to cleave CD16a leading to a decrease 
in NK cell ADCC.  This project seeks to generate genetically modified NK cells that have 
CD16a expression stabilized to maximize ADCC.  One method to accomplish this is the 
generation of a non-cleavable version of CD16a.  This cDNA construct has been transfected 
into iPSCs using Sleeping Beauty transposase to stably express CD16a.  These cell’s CD16a 
molecules are resistant to cleavage upon cell activation and are also highly expressed on the 
surface of the NK cells.  Preliminary testing has shown that when combined with antibodies 
specific to their cognate target ligand, these cells have a greater cytolytic response than 
untransfected peripheral blood NK cells (PBNK).  Also, CRISPR-Cas9 has been employed to 
knock-out ADAM17.  Going forward, comparing the cytotoxicity of these two NK cells will 
show which is best to employ in the treatment of cancers that express ligands for therapeutic 
antibodies that have proven refractory to other therapies and adjuvants. 
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Introduction 
The derivation and generation of human embryonic stem cells (hESC) and 
induced pluripotent stem cells (iPSC) have helped to drastically advance the fields of 
developmental biology and regenerative medicine (Thomson et al., 1998; Takahashi et 
al., 2007).  While these two cell populations are capable of generating mature cells from 
all three embryonic germ layers, they are obtained in two different methods.  hESCs are 
isolated from the inner cell mass of human blastocysts.  iPSCs on the other hand can be 
generated from mature cells such as fibroblasts.  While there are many methods to do 
this, it is most commonly done by viral transduction of mature cells with vectors that 
drive expression of four transcription factors (Malik et al., 2013).  These include octamer-
binding transcription factor 4 (Oct4), SRY-box 2 (SOX2), Krueppel-like factor 4 (Klf4) 
and cellular myelocytomatosis (c-Myc).  In the years since their derivation, scientists 
have taken advantage of the fact that these cells are capable of differentiating into mature 
cells of many lineages under the right conditions, facilitating the study of the in vitro 
development for various tissues and cells.   
In the field of hematology, hESCs and iPSCs have proved a powerful tool for 
scientists looking to study the development of hematopoietic cells.  For example, 
Kaufman et al. found that hESCs are capable of giving rise to multiple hematopoietic cell 
lineages when co-cultured with stromal cells (Kaufman et al., 2001).  This study and 
others like it were modeled on knowledge gained from research into the mechanisms of 
mouse and human hematopoietic development.  Human hematopoiesis starts two to three 
weeks into embryonic development as blood islands appear in the secondary yolk sac 
(Migliaccio et al., 1986).  One of the hallmarks of this cellular population is the cell 
surface receptor FLK1 (VEGFR2) (Ema et al., 2003; Park et al., 2004).  They are thought 
to arise from mesoderm cells, termed the hemangioblast, which are able to generate both 
hematopoietic and endothelial cells (Huber et al., 2004; Kennedy et al., 2007).  The blood 
cells generated in these blood islands are both myeloid and erythroid while lymphoid 
generation is less well understood (Palis et al., 1999).  Studies have suggested that the 
yolk sac contains cells at this time capable of giving rise to ancestors of the adult 
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hematopoietic system (Samokhvalov et al., 2007).  The human embryo itself also has true 
HSCs during ontogenesis, which develop in the aorta-gonad-mesonephros (AGM) region, 
capable of rescuing hematopoiesis in lethally irradiated mice (Ivanovs et al., 2011).  This 
cellular population is thought to arise from the hemogenic endothelium, endothelial cells 
capable of giving rise to hematopoietic cells (Jaffredo et al., 1998).  Certain endothelial 
cells at this stage exhibit upregulation of hematopoietic markers, become rounded and 
eventually separate from the endothelium (Bertrand et al., 2010; Lam et al., 2010; Boisset 
et al., 2010).  Later in ontogenesis definitive blood cells and hematopoietic stem cells can 
be found in the fetal liver (Uchida et al., 2001; Tavian et al., 2005).  These HSCs 
eventually seed the bone marrow and continue to generate blood throughout adult life.   
Since Kaufman et al. 2001, there have been advances in in vitro human 
hematopoietic development from hESCs and iPSCs.  These have been partly stimulated 
by the difficulties posed by xenogeneic components to potential cell therapies.  Culture 
systems that do not require xenogeneic stromal co-culture and have defined, humanized 
conditions have been shown to successfully generate human hematopoietic progenitors 
(Ng et al., 2005).  When generating hematopoietic progenitor cells from ESCs and iPSCs, 
this system utilizes spin embryoid bodies (EB) which can be used to recapitulate the 
different niches that mesodermal and hemato-endothelial progenitors develop in during 
embryonic blood development (Ng et al., 2008).  The spin EBs are cultured with media 
containing cytokines important to early hematopoietic development, such as VEGF 
which stimulates FLK1, a hallmark of the hemogenic endothelium.  These spherical 
cystic structures contain hematopoietic, endothelial and stromal cells that can support the 
derivation and proliferation of hematopoietic progenitor cells capable of generating 
mature hematopoietic cells of both lymphoid and myeloid lineages (Knorr et al., 2013, 
Ran et al., 2013).   
The realization that hESCs and iPSCs can give rise to lymphocytes has led to the 
establishment of techniques that allow for the derivation of natural killer (NK) cells for 
use in cell-based therapies to treat cancers (Woll et al., 2005; Knorr et al., 2013, 
Hermanson et al., 2015).  These differentiation protocols involve the use of cytokines to 
3 
 
influence hematopoietic progenitor differentiation into NK cells and have been modeled 
on in vivo human NK cell development.  Human NK cell development is a progressive 
process in which hematopoietic stem cells (HSC) housed in the bone marrow give rise to 
NK cells through a number of intermediate states (Yu et al., 2014).  The first step occurs 
when HSCs divide into common lymphoid progenitors (CLP) (Kondo et al., 2001).  
These cells retain the ability to differentiate into all lymphoid cell populations however, 
over time some of their progeny acquire IL-15 receptor beta (CD122) which is an 
important step toward committed NK cell differentiation (Blom et al., 2006; Boos et al., 
2008; Ikawa et al., 1999).  IL-15 promotes NK cell differentiation, maturation and 
survival (Becknell et al., 2005).  The interactions that HSCs and NK precursors have with 
stromal cells in the bone marrow are also important as they have been shown to provide 
cytokines such as IL-3, IL-7, FMS-like tyrosine kinase 3 ligand (Flt3L) and c-kit ligand 
(SCF) (Drexler et al., 2004; Gibson et al., 1995; Lyman et al., 1998; Pillai et al., 2004; 
Guimond et al., 2010).  As these NK cell precursors mature, they acquire functional 
markers such as CD161, then CD56, CD94/NKG2A, NKG2D and finally KIRs and 
CD16 (Grzywacz et al., 2006; Perussia et al., 2005).  The expression level of CD56 is 
used to determine the developmental stage of mature NK cells.  Those CD56bright NK 
cells are shown to have lower cytotoxicity capabilities but high cytokine production in 
response to soluble factors (Cagliuri et al., 2008).  As CD56 decreases in expression, the 
cell’s inherent cytotoxicity increases and the ability of the cells to release cytokines in 
response to target cells predominates (Cagliuri et al., 2008).   
   In vitro NK cell development has been modeled off of in vivo NK cell 
maturation.  These observations have driven the use of defined cytokines to stimulate 
cells and derive cytotoxic NK cells from hematopoietic progenitor cells.  The studies that 
pioneered this experimental paradigm used purified mouse HSCs and have led to the 
notion that NK cell development proceeds through two major steps; lineage committed 
progenitor generation and development of mature cells capable of cytotoxic activity 
(Colucci et al., 2003).  This method was later modified to differentiate human bone 
marrow HSCs into NK cells using cytokines including c-kit ligand (SCF), Flt3-Ligand 
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(Flt3L), interleukin-7 (IL-7), IL-3, IL-2 and mouse fetal stromal cells (AFT-024) (Miller 
et al., 1999).  Since then, members of the Kaufman lab modified this protocol to 
differentiate NK cells from hESC-derived hematopoietic precursors (Woll et al., 2005).  
However, xenogeneic components within the aforementioned differentiation systems 
would prohibit effective clinical translation of any NK cell based therapies.  It has been 
demonstrated that the addition of SCF, Flt3L, IL-7 and IL-3 can replace stromal cells and 
help to generate NK cells from hematopoietic precursors (Mrozek et al., 1996; Williams 
et al., 1997).  Therefore, Knorr et al., 2013 and Hermanson et al., 2015 further modified 
the NK differentiation protocol to efficiently generate NK cells while excluding all 
xenogeneic components from hematopoietic and NK differentiation protocols.  Once NK 
cells have been derived, they are exponentially expanded using IL-21 transfected K562 
cells (Denman et al., 2012).  This cytokine has been shown to promote NK cell 
proliferation and maturation in the bone marrow (Parrish-Novak et al., 2000). 
NK cells are lymphocytes typified by their CD56+CD3- surface expression and 
are integral members of the innate immune system (Herberman et al., 1981).  This is due 
to the fact that they are capable of lysing transformed and virally infected cells without 
prior sensitization or genome rearrangement to produce antigen-specific receptors 
(Yokoyama et al., 2003).  Therefore, they have a critical role in tumor surveillance.  One 
of the ways that NK cells survey for tumors is by assessing the relative expression of 
MHC class I molecules (Karre et al., 1986).  During development, these killer-cell 
immunoglobulin-like receptors (KIRs) ligate to their respective ligands and gain the 
ability to determine the identity of healthy self-cells (Ljunggren et al., 1990).  When an 
inhibitory subset of KIRs recognizes appropriately expressed self-MHC I molecules, they 
transduce inhibitory signals through recruitment of protein tyrosine phosphatases 
preventing NK cell killing of target cells (Romagne et al., 2011; Narni-Mancinelli et al., 
2013).  Those cells that have non-self MHC I or no MHC I expression do not trigger 
inhibitory signals within the NK cell through these KIRs allowing for cytotoxicity to 
proceed (Long et al., 1999; Moretta et al., 2000; Colonna et al., 2000; Yokoyama et al., 
1993; Lopez-Botet et al., 2000).  NK cells can also use germ-line encoded activating 
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receptors (natural cytotoxicity receptors: NCRs) such as NKG2D, NKp46 and 2B4 to 
differentiate between normal and affected cells (Vivier et al., 2012).  Each of these 
receptors recognize an antigen(s) on the surface of target cells that is either not produced 
by normal cells or is differentially expressed on affected cells (Girardi et al., 2001).  It 
has been seen that cancerous cells, which express appropriate KIR ligands, can be 
targeted by NK cells due to the expression of these markers (Gras Navarro et al., 2014; 
Bauer et al., 1999).  When activated, many receptors dimerize with transmembrane 
signaling domains stimulating tyrosine kinase-dependent cell activation (Krzewski et al., 
2008).  Finally, cytokines such as IL-15, IL-12 and IL-18 can lead to activation of the 
general NK cell population and increased anti-tumor activity (Cooper et al., 2009).  
Within the NK cell, signals from receptors and cytokines are integrated leading to 
a potentially cytotoxic event (Vivier et al., 2004).  However, in order for target cell lysis 
to occur the NK cell must strongly engage its target (Orange JS., 2008).  This involves 
the formation of the immunological synapse; a tight NK cell to target cell association.  
After formation, excitatory receptor signals can lead to NK cell killing of the target 
(Orange JS., 2008).  NK cells can kill target cells by a variety of mechanisms once they 
have generated an immunological synapse (Bromley et al., 2001).  The most potent and 
common is through degranulation of cytolytic granules (Childs et al., 2015).  These 
granules contain perforins and granzymes which work together to trigger target cell 
apoptosis (Froelich et al., 1996; Browne et al., 1999).  While the exact mechanism by 
which perforins act is unknown, it is hypothesized that perforins destabilize target cell 
plasma membranes which assist in granzyme uptake by endosomal structures (Keefe et 
al., 2005). There are multiple granzymes with slightly different mechanisms to kill target 
cells (Trapani et al., 2002).  In the case of granzyme B, uptake leads to direct and indirect 
caspase activation through the activity of BCL-2 family proteins (Sutton et al., 2000).  
This granzyme also has the ability to destabilize mitochondrion and facilitate release of 
cytochrome c into the cytoplasm leading to further induction of the pro-apoptotic 
program (Alimonti et al., 2001).  Granzyme A alternatively induces apoptosis via 
cleavage of nuclear proteins leading to double strand breaks in the target cell’s DNA 
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(Beresford et al., 1999).  NK cells can also trigger their target’s death receptor pathways 
through their expression of tumor necrosis factor related apoptosis-inducing ligand 
(TRAIL) and Fas ligand (FASL) (Trapani et al., 2002).  These pathways trigger caspase 
activation and target cell death when ligands of the death receptors bind at immune 
synapses (Czabotar et al., 2014).  After lytic granule release has finished, NK cells 
undergo a period of inactivity and eventually detach from the lysed target cell (Orange 
JS., 2008).       
Generally, NK cell killing is determined by a summation of both positive and 
negative signals.  No single NCR is capable of stimulating NK cells to kill a potential 
target without co-stimulation from another receptor and a lack of inhibitory signaling 
(Long et al., 2013).  The Fcγ receptor CD16a however is able to activate NK cell 
cytotoxicity autonomously of these checkpoints (Long et al., 2013).  As a member of the 
Fcγ receptor family, CD16a stimulates NK cell killing by complexing with the Fc portion 
of IgG molecules (Nimmerjahn et al., 2008).  This causes intracellular immunoreceptor 
tyrosine-based inhibitory motif (ITAM) phosphorylation and eventual RAS-RAF-MAPK 
signaling resulting in cell activation and antibody-dependent cell-mediated cytotoxicity 
(ADCC) (Nimmerjahn et al., 2008).  While there are a number of different Fcγ receptors 
expressed on different immune cells, NK cells only express CD16a (Nimmerjahn, 2008).         
In recent years, clinical trials have been conducted using allogeneic peripheral 
blood derived NK (PBNK) cells to treat a number of cancers (Miller et al., 2005; Geller 
et al., 2011).  These adoptive immune cell therapy trials have demonstrated the utility of 
NK cells in this setting as well as showing that allogeneic NK cell therapies do not 
generate prohibitive adverse side effects.  While these treatments do run the risk of 
eliciting side effects such as anemia and neutropenia, Miller et al. 2005 demonstrated that 
haploidentical allogeneic NK cells could effectively combat acute myeloid leukemia 
(AML) without sparking GVHD (Miller et al., 2005).  Clinical trials involving solid 
tumors have also been conducted showing the viability of haploidentical NK cells to 
attack solid tumors like ovarian cancer in patients (Geller et al., 2011).  However, none of 
the patients went into a complete remission, showing that there is work that needs to be 
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done in order to augment current adoptive NK cell therapy options in the case of solid 
tumors.   
While the PBNKs tested in the aforementioned trials are certainly effective at 
killing hematological cancers such as acute myeloid leukemia (AML), they did not 
performed so well when treating solid tumors (Miller et al., 2005; Geller et al., 2011).  
Therefore, one route to remedy this problem is using hESC and iPSC-derived NK cells.  
These cells have demonstrated potent in vitro and in vivo killing of solid tumors and 
express similar receptors to those seen on PBNKs (Woll et al., 2009).  One reason to 
derive NK cells from hESCs and iPSCs is that they can be banked and validated based on 
alloreactivity.  Unlike PBNK donor cell populations which are highly variable, these 
banked cells would be a uniform population.  Another advantage over PBNK cells is that 
the hESC and iPSC populations used to derived NK cells are highly amenable to a 
number of genetic modification mechanisms (Wilber et al., 2007; Gropp et al., 2003).  
These can be used to modify and augment the functional NK cell’s activity and increase 
their ability to kill cancers.  For these reasons, we hypothesize that proceeding with 
pluripotent stem cell derived NK cells over PBNKs is preferable.    
One potential genetic modification of relevance to NK cell clinical applications 
involves the Fcγ receptor CD16a.  Because CD16a recognizes the Fc region of IgG1 and 
IgG3 isotype antibodies, it is thought that combining these cells with FDA approved 
monoclonal antibody therapies could help to treat solid tumor cancers (Nagarajan et al., 
1995).  Monoclonal antibodies have been used for the treatment of a range of cancers for 
over a decade and have revolutionized the field of cancer therapeutics (Scott et al., 2012).  
For example, Cetuximab, Trastuzumab and Rituximab recognize surface proteins 
expressed by the tumor cells that they target (Olive et al., 2010).  The antibodies 
themselves can lead to target cell death in two ways.  They can directly act upon target 
cancer cells to kill them by preventing the function of surface proteins vital to 
proliferation and survival (Ludwig et al., 2003).  Also, these antibodies can kill tumor 
cells by directing NK cell ADCC through CD16a (Alderson et al., 2011).  CD16a comes 
in two single nucleotide polymorphism (SNP) variants, the high Fc affinity FcγRIIIa158V 
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and low affinity FcγRIIIa158F (Nimmerjahn et al., 2008).  It has been shown that 
lymphoma patients with the higher affinity allele exhibited improved clinical responses 
when treated with the therapeutic monoclonal antibody Rituximab (Cartron et al., 2002; 
Weng et al, 2004; Weng et al., 2003).  In patients with ovarian cancer, CD16a expression 
has been shown to be decreased on NK cells (Lai et al., 1996; Jewett et al., 2011).  This 
decrease in expression is due to the effects of a metalloprotease called ADAM17 (Romee 
et al., 2013).  In response to activating signals from CD16a, ADAM17 cleaves CD16a 
from the cell surface (Romee et al., 2013; Jing et al., 2015).  ADAM17 is a member of 
the ADAM family of metalloproteases and has a role in the cleavage of many substrates 
including some relevant to NK biology such as L-selectin and TNF-alpha (Scheller et al., 
2011).  Mice with ADAM17 knocked out had defects in their vasculature, lungs, eyes, 
hair and skin.  These problems were responsible for their premature deaths between 
E17.5 and a few days after birth (Peschon et al., 1998).  A condition in humans has also 
been studied which seems to be the result of a homozygous mutation in the ADAM17 
gene.  These patients developed skin lesions, diarrhea and cardiovascular issues.  
However, none of this data suggested that actual hematopoietic development was 
noticeably affected by ADAM17 mutations.   
Since CD16a downregulation leads to a decrease in NK cell cytolytic activity, our 
lab aims to prevent its cleavage from the surface of NK cells.  In order to preserve the 
effects of this receptor, our lab and collaborators have devised two methods to maintain 
its expression on the surface of NK cells.  We have designed a non-cleavable version of 
CD16a that is not susceptible to cleavage by ADAM17 (Jing et al., 2015).  The mutant 
CD16a has a single residue (197) mutated from a serine to proline.  This has been stably 
integrated into iPSCs using the Sleeping Beauty transposase.  Also, we have used 
CRISPR-Cas9 to knock-out ADAM17 in hESCs and iPSCs.  We hypothesize that 
preventing downregulation of this molecule could increase the effectiveness of therapies 
treating solid tumors when combined with therapeutic antibodies. 
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Materials and Methods 
hPSC Subculture Conditions 
Maintaining human pluripotent stem cells (hPSCs) in an undifferentiated state over a long 
period of time allows researchers to keep a constant reservoir of functional cells that can 
be used for multiple iterations of an experiment.  The hPSCs used for these experiments 
included H9 and UCBiPS7 cells.  H9 cells were isolated from human blastocysts as 
described in Thomson et al. and were purchased from WiCell (Thomson et al., 1998).  
UCBiPS7 cells were derived by prior members of the Kaufman lab from umbilical cord 
blood cells positive for CD34.  Once sorted, these CD34 positive cells were then 
transduced with lentivirus containing Oct4, Sox2, Klf4 and c-Myc which drove 
transcription of genes responsible for reprogramming these cells into pluripotent cells 
(Ye et al., 2013).  In order to maintain the undifferentiated state of hPSCs, the following 
steps were executed.  In culture, hPSCs were maintained on irradiated (3,000 rads) mouse 
embryonic fibroblast (iMEF) feeder cells plated on 0.1% gelatin at 100,000 cells/well in 
6 well plates.  These cells were stored in an incubator at 37oC and 5% CO2.  hPSCs were 
fed daily with hPSC media consisting of Dulbecco’s Modified Eagle Medium/F12 
(DMEM/F12; Invitrogen) base media supplemented with 1mM L-Glutamine 
(Invitrogen), 0.5% PenStrep (Invitrogen), 1% non-essential amino acids (NEAA) 
(Invitrogen), 15% knock-out serum replacer (KOSR) (Invitrogen), 4 ng/mL basic 
Fibroblast Growth Factor (bFGF) (Addgene) and 0.1 mM 2-Mercaptoethanol (Thermo 
Fisher Scientific).  When hPSCs reached a confluence of approximately 90% they were 
passaged onto a new plate of MEFs.  These cells are TrypLE (Invitrogen) adapted which 
allows them to be passaged as a single cell suspension.  To accomplish this, hPSCs were 
passaged approximately 10 times using TrypLE.  At this point, the whole population 
should be cells that detach well under these conditions.  In order to passage cells, TrypLE 
must be warmed to 37oC and the cells should be incubated with TrypLE for 
approximately 3 minutes but no longer than 5.  Using a pipette, the cells were washed off 
of the plate and diluted out in at least twice the volume of TrypLE using hPSC media to 
neutralize the TrypLE.  Cells were then passed onto the new plate at the desired passage 
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ratio.  In order to freeze down cells, individual wells of a 6 well plate were grown up to 
near confluence and then detached using TrypLE.  Each well of cells was then put into a 
vial suspended in 1 mL of freezing media.  This consists of 60% hESC media, 30% fetal 
bovine serum (FBS) (Invitrogen) and 10% dimethyl sulfoxide (DMSO; Sigma Aldrich). 
Flow Cytometry 
Flow cytometry was done using the LSR II H1160 at the University of Minnesota’s core 
facility.  Antibodies used included CD34-PE, CD45-PE, CD56-PE, CD33-PE, CD14-PE, 
CD16-PE, CD34-PE-Cy7, CD45-PE-Cy7, CD56-PE-Cy7, CD31-APC, CD43-APC, 
CD45-APC, CD73-APC, KDR-APC, CD117, CD144-APC, CD56-APC, CD158a/b/I-
APC, CD94-APC, NKp44-APC, NKp46-APC, NKg2D-APC, Fas ligand-APC, Trail-
APC, CD16-APC (all BD), ADAM17-primary (Abcam) and Alexafluor 594 secondary 
(Abcam).  Cells were stained with antibody for 30 minutes following the producers’ 
recommended quantities.  The collected events were analyzed using Flowjo software. 
Cancer Cell Culture 
In order to test the inherent in vitro cytotoxicity of various NK cell populations, different 
cancer cell lines were grown and put into chromium release assays.  These include; K562 
human chronic myelogenous leukemia line, Raji human Burkitt’s lymphoma cells, SK-
OV-3 human ovarian carcinoma (HER2 high) and MA-148 human ovarian carcinoma 
(HER2 low).  The first three have been bought from ATCC and were cultured per their 
recommendations.  MA-148 cells were isolated at the University of Minnesota in the lab 
of Dr. Ramakrishnan.  K562 cells were maintained in T-25 flasks with 10 mL of K562 
media which included Roswell Park Memorial Institute (RPMI) media (Invitrogen) with 
10% FBS, 1% PenStrep, 1% L-Glutamine and 1% NEAA.  Cells were counted daily and 
when they reached 0.7-0.8*106 cells/mL they were passed to 0.3*106 cells/mL in order to 
keep them in log growth phase.  Raji cells were also maintained in T25 flasks using K562 
media.  When they reached 2-3*106 cells/mL they were passaged down to .5-5*105 
cells/mL.  MA-148 cells were maintained in 15 mL K562 media while attached to a T-75 
flask.  When cultures reached 95% confluence they were passaged using 0.05% Trypsin-
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EDTA warmed to 37oC for 5 minutes.  This was neutralized with 10 mL K562 media and 
the cells were then passaged at a ratio of 1:3-6.  SK-OV-3 cells were maintained in 15mL 
SK-OV-3 media affixed to a T75 culture flask.  SK-OV-3 media includes McCoy’s 5a 
media (Invitrogen), 10% FBS, 1% L-Glutamine, 1% NEAA and 1% PenStrep.  The 
passaging was done the same as for the MA-148 cells. 
Spin Embryoid Body (EB) Hematopoietic Differentiation    
Hematopoietic progenitor cells that are CD34+/CD43+ and CD34+/CD45+ have been 
shown to be capable of generating NK cells in vitro (Vodyanik et al., 2006).  Under the 
specified conditions, the spin embryoid body (EB) system can be used to recapitulate the 
hematopoietic niche in vitro and drive hPSCs to differentiate into hematopoietic 
progenitor cells (Ng et al., 2008).  This system can therefore be used in the differentiation 
of NK cells from undifferentiated hPSCs.  Before generating spin EBs it is necessary to 
synchronize the population of cells into logarithmic growth phase.  250,000-500,000 
hPSCs (depends on rate of division) should be passaged one day before EB formation 
onto iMEFs at 100,000 cells/well.  When these hPSCs reach a confluence of 
approximately 70% they are ready to be detached by TrypLE passaging.  Only pure cell 
cultures without differentiating colonies were used.  In order to remove clumps, the 
passaged cells were run through a 70 micron filter.  This single cell suspension was added 
to Albumin Polyvinylalcohol Essential Lipids (APEL) media and cytokines.  APEL is a 
defined media and contains no xenogeneic components and was made as previously 
described (Ng et al., 2008).  For this stage of hematopoietic differentiation: VEGF (20 
ng/mL), BMP4 (20 ng/mL) and SCF (40 ng/mL) (all R&D) were added to the APEL.  
The single cell suspensions with APEL and cytokines were pipetted into ultra-low 
attachment 96 well plates (NUNC) at 2,500 cells per well and spun at 1500 rpm for 5 
minutes.  These cells were then put into an incubator at 37oC and 5% CO2 and left for 2-3 
days without being touched.  On day 6, a half media change with doubled concentrations 
of VEGF and SCF were given to further promote hematopoietic progenitor cell 
development.  
Maintenance of OP9 Stromal Cells 
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OP9 cells are mouse fibroblast-like cells that can be used to support the differentiation of 
NK cells from hematopoietic progenitors (Tabatabaei-Zavareh et al., 2007).  OP9 cells 
(ATCC) have been transduced using Sleeping Beauty to constitutively express Delta-like 
ligand 1 (OP9-DL1) which acts through the Notch pathway to support NK differentiation 
(Carotta et al. 2006).  Before use, these cells must be mitotically inactivated.  To 
accomplish this, cells were treated with 300 uL of 500ug/mL Mitomycin C (Millipore) 
for 3 hours.  These cells were seeded at 27,000 OP9 cells per well onto 0.1% gelatinized 
24 well plates.  Once EBs had matured for 11 days they were transferred onto these cells.  
OP9 media consists of alpha-minimum essential media (alpha-MEM) (Invitrogen) 
supplemented with 20% FBS, 1% L-Glutamine, 26 mM Sodium Bicarbonate and 1% 
PenStrep.   
Natural Killer Cell Differentiation from Spin EBs 
In order to influence hematopoietic progenitor cells to differentiate into NK cells, EBs 
can be placed into media containing cytokines important for NK cell development (Knorr 
et al., 2013).  On day 11 of the hematopoietic differentiation, spin EBs were transferred 
from their 96 well plates to 24 well plates.  Before transfer, approximately half the APEL 
is removed using a multichannel pipette.  The EBs are then transferred to a 24 well plate 
with Natural Killer differentiation media (NKDM) and cytokines.  This was made as 
described in previous publications and supplemented with Flt3L (10 ng/mL), IL-7 (20 
ng/mL), IL-15 (10 ng/mL), SCF (20 ng/mL) and IL-3 (5 ng/mL only on the day of the 
transfer) which were all purchased from R&D systems Minneapolis, MN (Knorr et al., 
2013).  These were passed onto 24 well plates, either coated with gelatin then seeded 
with OP9-DL1 cells, or bare plastic.  6-8 EBs were transferred into each well.  Every 
week, half of the media was changed.  After 4 weeks one well of cells was harvested to 
determine the quantity of CD56-expressing cells in culture using flow cytometry.  
Briefly, cells were harvested and filtered to remove debris and EBs.  These cells were 
then stained with CD56-APC, CD33-PE and CD14-PE to determine which cells were 
present in these cultures.   
Artificial Antigen Presenting Cell NK Cell Stimulation 
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Stimulation of NK cells was done using IL-21 transduced K562 myelogenous leukemia 
cells.  IL-21 is a gamma chain cytokine that synergizes in vivo with Flt3L, IL-2 and IL-15 
to generate NK cells from the bone marrow (Denman et al., 2012).  IL-21 may also help 
to upregulate cytolytic activity by upregulating NCRs, perforins and granzymes (Denman 
et al., 2012).  It also helps in the proliferation and maturation of NK cells in culture 
(Denman et al., 2012).  Therefore, after 4-5 weeks in NKDM, cultures that had CD56 
cells (as determined by flow cytometry) were transferred into NK expansion conditions.  
First, non-adherent cells were harvested from 24 well plates and filtered through a 70 
micron filter to remove the EBs.  This cell suspension was counted using a standard 
hemocytometer.  These cells were then put into artificial antigen presenting cell (aAPC) 
co-culture at an initial ratio of 2 IL-21 transduced K562: 1 NK cell.  The cells were 
incubated in NK expansion media which consists of RPMI with 10% FBS, 1% PenStrep, 
1% L-Glutamine, 1% non-essential amino acids and IL-2 (R&D).  4 days after the cells 
were put into culture the media was changed.  Every 7 days after initiation the K562 cells 
were replenished at a 1:1 ratio.  This was done weekly until 2 months after transfer into 
NKEM conditions.  Periodically over the course of the two months, cells were frozen 
down and stocked.  The freezing media consists of 50% FBS, 40% NKEM without IL-2 
and 10% DMSO. 
Validation of Hematopoietic Differentiation 
In order to determine the identity of cells within the differentiating EBs, flow cytometry 
was run on disaggregated EBs.  Briefly, 48-96 EBs were collected from 96 well plates, 
washed with DPBS and incubated with 1 mg/mL collagenase IV (Thermofisher 
Scientific) for 2 minutes.  This was then neutralized with double the volume of I10 (10% 
FBS in Iscove's Modified Dulbecco's Medium (IMDM)) (Invitrogen).  After washing 
again with DPBS, cells were incubated with 0.05% Trypsin + EDTA (Invitrogen) + .02% 
chick serum for 8-10 minutes.  This was also neutralized with double the volume of I10.  
The cells were then put through a strainer and flow cytometry was run.  To determine the 
quantity of hematopoietic progenitor cells, the expression of CD34-PE was compared to 
CD31-APC, CD43-APC, CD45-APC and CD73-APC. 
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NK Cell Immunophenotyping  
Receptors such as killer-cell immunoglobulin-like receptors (KIRs), natural cytotoxicity 
receptors (NCRs) and CD16a are the primary mediators of NK cell cytotoxicity.  Their 
presence or absence could have profound implications on the success or failure of in vitro 
cytotoxicity experiments.  In order to determine the complement of receptors present on 
the surface of NK cells after NK expansion, flow cytometry was used.  This was also 
used to quantify the relative expression of CD16a on different cell lines such as the 
knock-in CD16a wild-type, mutant and un-transfected cells.  The expression of CD56-PE 
was compared to receptors such as CD158a/b/h-APC, CD94-APC, NKp44-APC, NKp46-
APC, NKg2D-APC, Fas ligand-APC, Trail-APC and CD16-APC. 
In Vitro Cytotoxicity 
In order to compare the inherent cytotoxicity of NK cells transduced with mutant CD16a, 
with ADAM17 knocked out, isolated from peripheral blood (PBNK) and untransfected 
UCBiPS7-derived NK cells, chromium release assays were used.  This assay works by 
incubating target tumor cells with Chromium-51 containing CrO4
2− (Perkin Elmer).  
These labeled cells can then be incubated with different quantities of effector (NK) cells.  
The relative release of Chromium into the supernatant can be used to determine the 
efficacy of the NK cells.  Briefly, tumor cells (K562, MA-148, SK-OV-3 and Raji) were 
incubated for 1 hour at 37oC with 0.2 millicuries of radioactive CrO4
2−.  These cells were 
then washed 3 times with I5 (IMDM+5% FBS) and co-cultured with NK cells at the 
specified effector to target (E:T) ratios in I20.  To test the effect that adding antibodies 
would have on the NK cell’s cytotoxicity (ADCC), Rituximab (targeting Raji cells at 10 
ug/mL; Genentech) and Herceptin (targeting HER2-expressing cells at 100ug/mL; 
Genentech) were incubated with the effector cells for 30 minutes before adding the target 
cells.  After 4 hours, the plates were spun down and 100 uL of the media was collected 
(without pellet) for gamma scintillation measurements.  Specific lysis was calculated as 
follows: Percentage of specific lysis = 100*(Test Release – Spontaneous Release) / 
(Maximal Release – Spontaneous Release) (Knorr et al., 2013).   
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Confirmation of ADAM17 KO 
During previous Kaufman lab studies, UCBiPS7 and H9 cells were transfected with 
CRISPR-Cas9 targeting exon 1 of ADAM17.  Flow cytometric analysis on these cells 
showed which clones had a knock-out of ADAM17 as determined by a lack of surface 
expression.  The sgRNA was designed by our collaborator Jimmy Wu and had the 
sequence 5’-ccg CCG AAG CCC GGG TCA TCC GG-3’.  First, cells were grown in 
zeocin containing hPSC media to select out for non-transfected cells.  The survivors were 
then sorted by isolating GFP positive cells (the CRISPR-Cas9 vector constitutively 
expresses GFP).  These cells were then grown and plated at low density.  Homogenous 
clones were picked and grown in a 12 well plate on 30,000 iMEFs/well with normal 
hPSC media.  When confluent, they were detached using TrypLE and flow cytometry 
was run as described using an ADAM17 primary antibody and an Alexafluor 594 
secondary antibody.  Those clones whose flow plots matched that of their isotype were 
selected as potential knock-out clones.  To determine if these non-expressing cells were 
truly ADAM17-/-, the clones’ DNA flanking the exon 1 cut site were isolated for 
sequencing.  First, genomic DNA was isolated using a Qiagen DNeasy blood and tissue 
kit.  This was then used as a template to derive a PCR product using primers procured 
from Invitrogen and a high fidelity Taq polymerase (Thermofisher Scientific).  The 
sequence of the upstream primer was 5’GGGTGGAGTTGGGACTCATAC3’ and of the 
downstream primer was 5’ACACCCCCTTCTACACTGAAAA3’.  This PCR product 
was then run on a 1 % agarose gel to see if the band localized to the appropriate region of 
the gel (655 bp).     
Statistical Analysis 
Differences between groups were compared using two way ANOVA testing via Prism 4 
(GraphPad Software, San Diego, CA).  Results with a p-value less than .05 were 
considered significant. 
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Results 
Transfection of hES and iPS Cells with Crispr-Cas9 Plasmids Targeting ADAM17 
Leads to its Knock-out 
ADAM17 is expressed on many different cells within the human body (Scheller et 
al., 2011).  As demonstrated by previous studies in the Kaufman lab, ADAM17 is 
specifically expressed on hES cells, PBNK and iPSC-derived NK cells (Fig. 1A).  In 
order to generate ADAM17-/- hES and iPS cells, H9 and UCBiPS7 cells were transfected 
with a vector that expresses a sgRNA sequence targeting exon one of the ADAM17 
transcript (Fig. 1B).  This vector constitutively expresses GFP and confers recipient cells 
with antibiotic resistance.  These features were used to fluorescence-activated cell sort 
(FACS) out cells that had been successfully transfected with the vector after having been 
cultured for 72 hours.  After these cells were isolated, they were grown up in bulk and 
passaged at a low enough confluence to isolate clones that had arisen from one cell.  
These clones were then stained for ADAM17 and surface expression was determined by 
flow cytometry analysis.  Previous Kaufman lab analysis on the H9 cells showed 7 clones 
whose surface expression of ADAM17 matched that of the isotype.  Flow cytometric 
analysis on the iPS cells found 4 clones whose surface expression of ADAM17 matched 
that of the isotype (Fig. 1C).  These cells were then expanded and frozen down in the 
liquid nitrogen.  
To confirm the knock-out genetically, the DNA flanking exon one of the 
ADAM17 gene was isolated using primers targeting sequences upstream and downstream 
of the cut site.  Genomic DNA from the clones thought to be ADAM17-/- was isolated 
and purified.  The DNA flanking the exon 1 cut site of the clones was then amplified via 
PCR reactions.  The DNA products of these reactions were then run on a 1% agarose gel 
to determine if the primers in fact generated products of the appropriate 655 nucleotide 
length (Fig. 1D).  Unlike the band produced from iPSC clone 10, most of the products 
generated a strong signal and were of the appropriate length.  DNA from this clone will 
be re-isolated in order to generate a more pure PCR product which can in the future be 
sequenced along with DNA from the other clones.  Initial isolation of iPSC clone 9 was 
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not effective and therefore DNA from another batch of the cells was isolated.  Both of the 
products were run and while the second band from the right did not produce a band, the 
other iPSC clone 9 was able to generate a product (Fig. 1D).        
hESC Derived Hematopoietic Progenitors Failed to Produce NK Cells 
Upon the derivation of these ADAM17 knock-out H9 cells, the undifferentiated 
pluripotent stem cells were put into spin EBs to foster hematopoietic differentiation.  For 
these trials, an H9 untransfected control, H9 CRISPR-Cas9 transfected control (expresses 
ADAM17) and two knock-out clones (5 and 10) were used.  Over the 11 day time course, 
EBs grew and their progression can be seen before the day 6 half media change as well as 
before the day 11 transfer to NK differentiation conditions in Figures 2A and 2B.  These 
EBs developed cystic structures and often showed an appreciable accumulation of round 
hematopoietic cells surrounding the EB.  After 11 days in culture, the EBs were 
disaggregated to analyze the relative populations of primitive and mature hematopoietic, 
endothelial and stromal cells within the EB by flow cytometry (Fig. 2C).  These EBs can 
produce immature cells (CD34+) and immature endothelial cells (CD34+CD31+) with the 
ability to give rise to blood cells.  Critically they are also capable of generating cells both 
CD34+CD43+ and CD34+CD45+ which have been shown previously to give rise to NK 
cells in vitro (Tien et al., 2009; Vodyanik et al., 2005).  One concern regarding this 
project was that the knock-out of ADAM17 may inhibit hematopoietic differentiation.  It 
has been shown that ADAM17 is responsible for cleaving many proteins from the surface 
of cells that contribute to hematopoiesis such as Flt3L (Scheller et al., 2011; Gilliland et 
al., 2002).  Importantly, the hematopoietic differentiations were not determined to be 
significantly affected by the knock-out of ADAM17 (Fig.2D).  The percentages of cells 
CD34+CD31+, CD34+CD43+, CD34+CD45+ and CD34+CD73+ did not differ significantly 
between iPSCNK transfected ADAM17 expressing and the two iPSCNK ADAM17 KO 
cell lines (Fig. 2D). 
While these studies did demonstrate production of hematopoietic progenitor cells based 
on phenotype, the progenitor cells derived from the EBs did not generate H9-derived NK 
cells when placed into NK differentiation media (NKDM).  Approximately 2 weeks after 
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transfer, the cultures proliferated heavily almost covering the whole well (Fig. 2E).  By 
day 30 in NKDM however, these cultures which previously proliferated strongly were 
devoid of hematopoietic cells and all that could be seen were stromal cells (Fig. 2E).  
When analyzed by flow cytometry, these cultures uniformly gave rise to CD33+CD56- 
myeloid cells (Fig. 2F).  Even repeated passaging on OP9-DL1 stromal cells has not 
permitted generation of CD56 positive cells.  Potentially, the ADAM17 knock-out could 
have somehow adversely affected NK cell differentiation independent of hematopoietic 
progenitor differentiation.  It has been shown that Notch, a target of ADAM17, can help 
to contribute to NK cell generation (Beck et al., 2009).  However, even H9 control cells 
that do express ADAM17 normally were not, up to this point, capable of making NK 
cells (Fig. 2F).  Likewise, ADAM17-/- iPSC-derived NK cells have been generated, 
further detracting from the theory that this developmental deficit is due to ADAM17’s 
knock-out (Fig. 3C).   
NK Cell Development from ADAM17-/- iPSC-Derived Hematopoietic Progenitor 
Cells 
After ADAM17 was knocked out in iPS cells, the clones were differentiated into 
hematopoietic progenitors.  For these trials, an iPSC untransfected control, iPSC 
CRISPR-Cas9 transfected control (expresses ADAM17) and two knock-out clones (9 and 
10) were used.  After 11 days in culture, the EBs were disaggregated to analyze the 
relative populations of primitive and mature hematopoietic, endothelial and stromal cells 
within the EB by flow cytometry (Fig. 3A).  These EBs can produce immature cells 
(CD34+) and immature endothelial cells (CD34+CD31+) with the ability to give rise to 
blood cells.  Critically they are also capable of generating cells both CD34+CD43+ and 
CD34+CD45+ which have been shown previously to give rise to NK cells in vitro (Tien et 
al., 2009; Vodyanik et al., 2005).  Similar to what was seen in the H9 ADAM17 knock-
out cultures; there was no significant difference between the hematopoietic 
differentiations seen in the control cell populations compared with the knock-out cells 
(Fig. 3B).  When these cells were placed into NKDM they managed to proliferate into 
CD56+ NK cells as shown from plots derived from clone 9 (Fig. 3C).   
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Non-cleavable CD16a knock-in iPSC Derived Hematopoietic Progenitors Can Give 
Rise to NK Cells 
iPS cells transduced with Sleeping Beauty transposase to integrate a vector which 
constitutively expresses both a non-cleavable and wild-type CD16a protein (along with 
GFP) were also put into hematopoietic differentiation conditions to generate 
CD34+CD43+ and CD34+CD45+ hematopoietic progenitor cells (Jing et al., 2015 and Fig. 
4A).  After 11 days in culture, the EBs were disaggregated to analyze the relative 
population of primitive and mature hematopoietic, endothelial, and stromal cells within 
the EB by flow cytometry (Fig. 4B).  Much like the H9 EBs, these EBs contained cells 
that were CD34+, CD34+CD31+, CD34+CD43+ and CD34+CD45+ and the two different 
cell lines had no significant difference in expression of these markers (Fig. 4C).  Once 
placed into NKDM conditions, these hematopoietic progenitors were capable of giving 
rise CD56+ NK cells (Fig. 4D).  These cells appear to be immature due to their expression 
of c-kit receptor (CD117) and have some cytolytic capabilities due to the expression of 
the NCR NKp44.   
After aAPC Co-culture iPSC-derived NK Cells Acquire Receptors Necessary for 
Cytotoxicity 
After deriving CD56+ NK cells from iPSC CD16a knock-in-derived 
hematopoietic progenitors, these cells were placed into aAPC co-culture with K562 cells 
that stably express membrane-bound IL-21 (Denman et al., 2012).  These cells help to 
drive the proliferation of NK cells while also stimulating the maturation of these cells in 
combination with the IL-2 added to the media (Denman et al., 2012).  After 2-4 weeks in 
culture, there were enough NK cells to perform experiments.  One of which was an 
immnunophenotyping panel using flow cytometry to stain the cells for various receptors 
integral to cytotoxicity.  In the case of iPSCNK untransfected cells, the aAPC expansion 
yielded a highly pure CD56+ population of cells (Fig. 5A).  These cells expressed the 
death receptor ligand Trail as well as the NCRs NKp46 and NKG2D (Fig. 5A).  
Interestingly, this cellular population highly expressed CD16a and almost 90% of the 
cells were positive for this receptor (Fig. 5A).  Immunophenotyping was also done on 
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iPSCNK CD16a mutant NK cells (Fig. 5A).  These cells were almost 100% CD56+ (Fig. 
5A).  They expressed the death receptor ligand Trail along with the NCRs NKp46 and 
NKG2D (Fig. 5A).  Over 98% of these cells expressed CD16a helping to confirm the 
hypothesis that CD16a mutant knock-in cells would maintain expression of CD16a to a 
much greater extent than untransfected control cells (Fig. 5A).  It is worth noting that 
these cells were not stimulated in a method that would trigger ADAM17 activation and 
CD16a cleavage.  We hypothesize that if the cells were stimulated with either PMA or 
IL-12 and IL-18 the disparity between the iPSCNK cells and iPSCNK CD16a mutant 
cells would be far more striking.   
 These cells were also tested to determine their in vitro cytotoxic capacity.  This 
was performed using the chromium release assay.  NK cells were co-cultured with both 
K562 and SKOV3 cells in the presence or absence of Herceptin to determine whether 
non-cleavable CD16a overexpression confers an advantage in killing targets that 
overexpress the antibodies’ target (epidermal growth factor receptor 2: HER2) in the 
presence of the antibody.  When PBNK, iPSCNK and iPSCNK CD16a mutant cells were 
incubated with K562 cells, the effector NK cells killed their targets at approximately the 
same level regardless of whether Herceptin was added (Fig. 6A).  This is to be expected 
as K562 cells do not express HER2.  Also, PBNK cells performed better in this trial than 
iPSCNK CD16a mutant NK cells.  When these same effector cells were co-cultured with 
HER2-expressing SKOV3 cells however, the addition of Herceptin augmented the killing 
of the effector cells (Fig. 6B).  In fact, the iPSCNK CD16a mutant cell’s killing was 
improved by the addition of Herceptin such that it was able to kill SKOV3 cells more 
effectively than PBNK cells in the presence of Herceptin.  While these results are 
promising, they are only comprised of one biological replicate.  In order to solidify these 
conclusions, more replicates are needed.           
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Discussion 
Thus far the project has yielded positive results.  Preliminary results have shown 
consistent generation of NK cells from iPS cells.  Likewise, testing of iPSC-derived NK 
cells has reinforced the hypothesis that non-cleavable CD16a molecules can help to 
augment ADCC.  The next step for this project is to obtain H9-derived NK cells for 
cytotoxicity testing.  Despite not generating any H9-derived NK cells, the differentiation 
of iPSC-derived NK cells was successful.  This makes identifying the problem(s) within 
the H9 differentiation difficult as these cells were often cultured in parallel with the same 
cytokines and media that successfully generated iPSC-derived NK cells.  One possibility 
is that the actual H9 cells transfected with the CRISPR-Cas9 sgRNA targeting ADAM17 
were not capable of generating NK cells.  The control cell lines that were run in parallel 
with the ADAM17 knock-out clones also did not generate NK cells.  These H9 
untransfected cells were also from the same stock that had been used for the ADAM17 
knock-out transfection.  To help determine whether the starting cell population was in 
some way defective, a new control is being tested (H9GFP:Luc) in parallel with H9 
ADAM17 knock-out cells.  If this control yields NK cells but the knock-out still doesn’t, 
the result would suggest that the starting cell population is deficient.   
 It is also possible that the H9 cells which have been differentiated to obtain these 
results were in some way damaged during the course of cell culture.  One possibility is 
that a process called culture adaptation occurred.  It has been shown that culture adapted 
hES cells exhibit altered or skewed differentiation capacities (Baker et al., 2007).  This 
can manifest through an abnormal karyotype as well as changes to the chromatin of hES 
cells (Baker et al., 2007).  However, other cell lines cultured in parallel with these cells 
and using the same MEFs generated NK cells.  Nonetheless, the next step in trouble 
shooting this possibility is to try and differentiate clones from a stock that was frozen 
down before these experiments were undertaken.  If these cells do generate NK cells then 
it is possible that the cells which have previously been subjected to differentiation 
acquired some issues and should be thrown away in favor of this more primitive 
population.  However, if these primitive cells do not generate NK cells then it may be 
22 
 
necessary to re-transfect another H9 cell line with the CRISPR-Cas9 targeting exon 1 of 
ADAM17.  This could be done using cells that have been proven in previous publications 
to efficiently generate NK cells.   
Having derived CD56+ cells from the ADAM17-/- iPS cells, the next step is to 
expand these cells in aAPC and then conduct the same chromium cytotoxicity 
experiments as was done for the iPSC CD16a mutant cells.  This will allow for a direct 
comparison between the two cell line’s inherent cytotoxicity and help to determine which 
would be a more effective cell-based therapy.   
Preliminary cytotoxicity results from the iPSC-derived CD16a mutant NK cells 
have been consistent with the overall experimental hypothesis.  These effector cells 
became activated in the presence of antibodies and elicit an improved cytotoxic response 
when compared to conditions without the antibody (Fig. 6B).  Likewise, this 
phenomenon was only observed when the effector cells were co-cultured with cancerous 
cells that express the antibody’s target (Fig. 6A).  The next step for these experiments is 
to replicate the assay while also adding on different cancer cell lines.  While SKOV3 
cells highly express HER2, another ovarian epithelial cancer cell line; MA-148, does not 
express HER2 at such high levels as determined by previous Kaufman lab experiments 
(Fig. 6C).  Comparing the results garnered from assays in which the non-cleavable 
CD16a transfected NK cells target both SKOV3 and MA-148 in the presence of 
Herceptin would help to show the true strength of these effector cells.  Likewise, this 
therapy could be employed against other cancers besides ovarian carcinomas.  Raji cells, 
a Burkitt’s lymphoma cell line that express CD20, can be targeted using Rituximab and 
are an example of another cell line that could be tested to determine the versatility of 
these effector cells.   
Another important aspect to this project is the acquisition all three genotypic 
variants derived from the phenylalanine (F) and valine (V) SNPs at residue 158 of 
CD16a.  It has been shown that patients homozygous for the high Fc-affinity 158V allele 
have a better prognosis when treated for B-cell lymphoma with Rituximab than the 
heterozygous (FV) and homozygous (FF) patients (Cartron et al., 2002; Weng et al, 2004; 
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Weng et al., 2003).  The vector that overexpresses the non-cleavable CD16a within iPS 
cells contains DNA coding for the high affinity allele.  The iPSC-derived NK cells being 
compared to the iPSC CD16a mutant-derived NK cells are heterozygous for this SNP.  
However, generating control iPSC-derived NK cells from populations homozygous for 
both SNPs would allow for a complete comparison showing the iPSC CD16a mutant-
derived NK (158V) relative to different iPSC-derived NK cells resembling the 
heterogeneity of the human populace.  Currently, our collaborators are working to 
determine the genotypes of four different iPSC lines and hopefully more can be acquired.    
Finally, it still remains to be conclusively determined whether or not the putative 
ADAM17-/- clones are true knock-out cells.  While the flow cytometry data shows that 
these clones lack ADAM17 expression, it is necessary to confirm that an indel mutation 
has occurred in both of the alleles.  Initial stages in this process have been completed.  
PCR products corresponding to the region flanking the exon 1 cut site have been 
amplified from genomic DNA isolated from individual clones.  It has also been shown 
the primers themselves are capable of generating a PCR product that corresponds with 
the nucleotide length of the theoretical product (Fig. 1D).  Going forward, this PCR 
product should be sequenced to look for indels of one or two nucleotides that would 
suggest a frameshift mutation that very likely would give rise to a non-sense mutation.  
Clones homozygous for these mutations would then be selected going forward for further 
differentiation.  
In recent years, pioneering work on adoptive NK cell immunotherapy has seen 
interest in the field expand greatly.  These studies employed PBNK cells and were often 
highly effective at treating hematological malignancies (Miller et al., 2005).  Likewise, 
trials involving T cell chimeric antigen receptor (CAR) adoptive therapies have also 
shown great promise in the treatment of hematologic malignancies (Grupp et al., 2013). 
However, when applied to solid tumors, NK cells did not elicit such positive responses 
(Geller et al., 2011).  This has led to a search for methods to improve upon previous 
results so solid tumors refractory to current therapies and adjuvants can be better treated.  
One avenue to augment previous trials is to use hES and iPS cell-derived NK cells.  The 
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discovery that allogeneic PBNK cells could safely be used to treat various malignancies 
has led to the possibility of using allogeneic hES and iPS cell-derived NK cells (Miller et 
al., 2005).  These cells, both the pluripotent stem cells and NK cells, can be banked 
leading to a uniform therapeutic unlike donor-derived PBNK cells.  Also, these 
pluripotent stem cells can critically be genetically manipulated in order to accentuate 
different immunoregulatory and cytolytic pathways (Wilber et al., 2007; Gropp et al., 
2003).  It is through these alterations that hES and iPS cell-derived NK cells can gain an 
advantage over PBNK cells.  Stabilizing the expression of CD16a is one way to increase 
the anti-tumor effects of these cells.  Knocking-out ADAM17 or transfecting cells with a 
non-cleavable version of CD16a should confer an advantage over other unmodified cells 
when attacking cancer cells through ADCC.  Under these conditions, the patient would 
concurrently be given a therapeutic antibody that targets their specific type of cancer.  
Therapeutic antibody treatments have been used for quite some time and are ever 
evolving (Slamon et al., 2011; Wilken et al., 2010).  Due to the wide range of antibodies 
available today and with more on the horizon, this strategy has the potential to be applied 
to any cancer that can be targeted effectively with therapeutic antibodies.   
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Figures 
Figure 1:  Transfection and validation of both H9 and iPSC ADAM17 knock-out.  A)  
Flow cytometry analysis from previous Kaufman lab studies showing surface expression 
of ADAM17 on various cell lines.  Starting from the top left corner and going clockwise: 
293 HEK cells, H9 ES cells, iPSC NK cells, PB NK cells and CB NK cells.  For flow 
cytometry histograms, the red plot is the isotype and the blue is the expression 
corresponding to each cell line.  B) pD1321-AD plasmid containing ADAM17 exon 1 
sgRNA and Cas9 nuclease used to knock out ADAM17 in both H9 and iPS cells.  C)  
Flow cytometry showing the relative expression of ADAM17 on H9 and ctrl iPS cells in 
both isotype controls (top two plots on left) and stained cells (bottom two plots on left).  
The grid of 12 plots on the right contains cells from the iPSC GFP positive cell 
population (transient expression) that were single clone selected and tested for ADAM17 
expression.  Those in the red boxes were isolated for further analysis and testing.  D)  
Using primers designed to anneal to the regions both upstream and downstream of the 
exon 1 cut site, a PCR product was generated from clones that were negative for 
ADAM17 expression as assessed by flow cytometry.  This product was expected to be 
655 nucletides long and the bands fall just below the 700 nucleotide band on the ladder 
(6th from top).  From left to right: H9 clone 1, H9 clone 2, H9 clone 5, H9 clone 7, H9 
clone 8, H9 clone 10, iPSC clone 9, iPSC clone 9 and iPSC clone 10.    
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Figure 2: Differentiation of H9 ADAM17 knock-out clones and controls yields 
hematopoietic progenitors but no NK cells.  A and B) Representative phase contrast 
images showing H9 derived EBs during hematopoietic differentiation.  The pictures in A 
show the EBs after six days in culture while the pictures in B show them after 11 days. 
Scales bars are for 1 mm on the left and 500 um on the right).  C)  Representative flow 
cytometry analysis from day 11 spin EB differentiation of (clockwise from top left) H9 
transfected control clone 2, H9 ADAM17 KO clone 5 and H9 ADAM17 KO clone 10 
cells.  D) Statistical analysis on the populations of H9 derived cells CD34+, 
CD34+CD31+, CD34+CD43+ and CD34+CD45+ after 11 days in stage one conditions (n=3 
for H9 ctrl c2,  KO c5 and KO c10) showed no significant difference in the 
differentiation of any of these hematopoiesis related cell types.  E)  Phase contrast images 
showing H9 derived cultures at D16 (on the left) in NKDM and (on the right) at D30.  
These differentiations included OP9-DL1 cells.  The D16 cultures contain many 
hematopoietic cells while the D30 cultures only possess OP9-DL1 cells coating. The top 
two pictures correspond with H9 ADAM17 expressing clone 2 derived cells, the middle 
two correspond to H9 ADAM17 KO clone 5 derived cells and finally the bottom two 
correspond to H9 ADAM17 KO clone 10 derived cells.  Scale bars are 1 mm.  F)   Flow 
cytometry analysis of the three aforementioned cell lines (from Fig. 2C).  These cells 
uniformly express CD33 (myeloid marker) but neither CD56 nor CD14 (macrophage) 
after 21 days in NK differentiation conditions.  
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Figure 3:  Differentiation of iPSC ADAM17 knock-out clones yield hematopoietic 
progenitors that give rise to NK cells.  A)  Representative flow cytometry data from day 
11 spin EB differentiation showing iPSC untransfected control cells (top), Crispr-Cas9 
transfected ADAM17 expressing clone 2 (second from top), ADAM17 knock-out clone 9 
(third from top) and ADAM17 KO clone 10 cells (bottom).  B)  Statistical analysis on the 
populations of iPSC untransfected ctrl, transfected ctrl c2, ADAM17 KO c9 and KO c10 
derived cells CD34+, CD34+CD31+, CD34+CD43+ and CD34+CD45+ after 11 days in 
stage one conditions (n=3) show that there is no significant difference in the 
differentiation of any of these hematopoiesis related cell types.  C)  Flow cytometry data 
showing differentiation of iPSC ADAM17 knock out clone 9 cells after 28 days in NK 
differentiation conditions.  Isotype is on the left.  
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Figure 4: Differentiation of iPSC CD16a mutant and wild-type clones yield 
hematopoietic progenitors that give rise to NK cells.  A)  Phase contrast and fluorescent 
images showing GFP expression in NK differentiation cultures positive for CD56 cells.  
The top two photos correspond to untransfected iPS cells that do not express GFP.  The 
bottom two correspond to iPSC CD16a mutant derived cells that are transfected with a 
pKT2-mCAG-IRES-GFP transposon that constitutively expresses GFP.  Scale bars are 
400 um.  B)  Representative flow cytometry data from day 11 spin EB differentiation 
showing iPSC CD16a wild-type transfected (top) and mutant transfected (bottom) cells.  
C)  Statistical analysis on the populations of iPSC CD16a mutant and wild-type derived 
cells CD34+, CD34+CD31+, CD34+CD43+ and CD34+CD45+ after 11 days in stage one 
conditions (n=5) show that there is no significant difference in the differentiation of any 
of these hematopoiesis related cell types.  D)  Flow cytometry data showing 
differentiation of iPSC CD16a mutant NK cells after 18 days in NK differentiation 
conditions. 
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Figure 5: Expanded NK cells have cytolytic immunophenotype.  Flow cytometry 
analysis of iPSCNK and iPSCNK CD16a mutant cell’s immunophenotype.  These cells 
express TRAIL, a cell death receptor ligand as well as NKp46 and NKG2D which are 
NCRs.  Finally, both of these expanded cells highly express CD16a.   
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Figure 6: Chromium release assays show the effect that Herceptin has in killing HER2 
overexpressing cancers when combined with NK cells.  A)  Standard chromium release 
assay showing relative killing of PBNK (green), iPSCNK (red) and iPSCNK CD16a 
mutant cells (blue) against K562 cells in the presence and absence of Herceptin.  The 
darker curves with dots represent the conditions with antibody. (n=1)  B)  Standard 
chromium release assay showing relative killing of PBNK (green), iPSCNK (red) and 
iPSCNK CD16a mutant cells (blue) against SKOV3 cells in the presence and absence of 
Herceptin.  The darker curves with dots represent the conditions with antibody.  (n=1)  C) 
Previous lab flow cytometric analysis showing the relative expression of HER2 on the 
surface of MA-148 ovarian carcinoma and SKOV3 ovarian carcinoma.  The SKOV3 
cells more highly express HER2.    
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